CARLSBAD, Calif.--(BUSINESS WIRE)--Feb. 10, 2006--The Immune Response Corporation (OTCBB:IMNR) announced today that the final results from a Phase II clinical study indicate that the Company’s whole-inactivated HIV-1 immunogen induces HIV-specific immune responses in HIV-infected, antiretroviral drug-naive patients. Specifically, this original formulation product showed potential to stimulate key immunologic parameters and to stabilize the loss of CD4+ cells, which could help prolong the time before these patients need to initiate antiretroviral therapy. The poster was presented at this week’s 13th Conference on Retroviruses and Opportunistic Infections (CROI) in Denver.
